Showing results (21-30 of 194) with videos related to
Sort By:
Pageof 20
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1981
Adjuvant polyarthritis. VI. Effect of oxonate-induced hyperuricemia on the development of acute inflammation, immune response and adjuvant arthritisY H Chang, R BluestoneThe Journal of Rheumatology. Supplement|May 1, 1997
Hypothesis for the pathogenesis of systemic sclerosisD E Furst, P J ClementsScandinavian Journal of Rheumatology|October 2, 2001
D-penicillamine is not an effective treatment in systemic sclerosisD E Furst, P J ClementsThe Journal of Rheumatology. Supplement|May 1, 1997
Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantationP J Clements, D E FurstLaboratory Investigation; a Journal of Technical Methods and Pathology|September 1, 1975
Chronic experimental hyperuricemic nephropathyR Bluestone, J Waisman, J R KlinenbergNephron|January 1, 1975
Hyperuricemic nephropathy: pathologic features and factors influencing urate depositionJ R Klinenberg, I Kippen, R BluestoneArthritis and Rheumatism|November 1, 1975
Halofenate. Its selection and trial as a primary uricosuric agentR Bluestone, D Campion, J R KlinenbergRheumatology (Oxford, England)|December 18, 2003
The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse sclerodermaN Sultan, J E Pope, P J Clements, et al.Pageof 20